$FGEN
FIBROGEN INC Stock $fgen

$fgen Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024020161 Filed on February 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$55.90M	$27.14M	$147.8M
YoY Change	54.59%	-21.03%	4.99%
Cost Of Revenue	$25.75M	$5.407M	$18.85M
YoY Change	637.7%	9.79%	-7.06%
Gross Profit	$30.15M	$21.73M	$128.9M
YoY Change	-7.72%	-26.19%	7.02%
Gross Profit Margin	53.93%	80.08%	87.24%
Selling, General & Admin	$22.82M	$24.22M	$115.3M
YoY Change	-33.42%	-28.68%	-7.57%
% of Gross Profit	75.69%	111.47%	89.41%
Research & Development	$38.39M	$51.70M	$282.9M
YoY Change	-48.46%	-16.1%	-4.69%
% of Gross Profit	127.34%	237.92%	219.44%
Depreciation & Amortization	$810.0K	$1.875M	$9.500M
YoY Change	-68.14%	-30.3%	-5.0%
% of Gross Profit	2.69%	8.63%	7.37%
Operating Expenses	$61.21M	$75.93M	$398.1M
YoY Change	-43.72%	-20.57%	-5.54%
Operating Profit	-$31.06M	-$54.20M	-$281.8M
YoY Change	-59.18%	-18.08%	-6.38%
Interest Expense	$4.996M	-$2.572M	$15.53M
YoY Change	110.62%	1218.97%	978.61%
% of Operating Profit
Other Income/Expense, Net	$2.570M		$10.48M
YoY Change	148.07%		37.97%
Pretax Income	-$33.49M	-$56.77M	-$286.9M
YoY Change	-56.75%	-14.44%	-2.71%
Income Tax	$33.00K	$80.00K	$3.000K
% Of Pretax Income
Net Earnings	-$32.93M	-$56.23M	-$284.2M
YoY Change	-57.07%	-15.03%	-3.21%
Net Earnings / Revenue	-58.91%	-207.21%	-192.37%
Basic Earnings Per Share	-$0.33		-$2.92
Diluted Earnings Per Share	-$0.33	-$0.57	-$2.92
COMMON SHARES
Basic Shares Outstanding	98.77M	98.34M	97.30M
Diluted Shares Outstanding	98.98M		97.30M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$184.7M	$235.6M	$235.6M
YoY Change	-48.1%	-44.17%	-44.17%
Cash & Equivalents	$105.7M	$113.7M	$50.29M
Short-Term Investments	$78.99M	$121.9M	$121.9M
Other Short-Term Assets	$1.870M	$6.711M	$13.36M
YoY Change	-87.09%	54.17%	-5.17%
Inventory	$27.34M	$41.57M	$41.57M
Prepaid Expenses	$5.780M	$6.644M
Receivables	$37.08M	$12.55M	$18.63M
Other Receivables	$21.38M	$22.42M	$22.42M
Total Short-Term Assets	$278.2M	$331.6M	$331.6M
YoY Change	-35.39%	-32.72%	-32.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.17M	$13.13M	$81.37M
YoY Change	-34.92%	-36.3%	-19.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.776M	$5.290M	$5.290M
YoY Change	-1.84%	4.52%	-43.78%
Other Assets	$3.350M	$3.803M	$5.308M
YoY Change	-28.3%	-28.0%	-23.28%
Total Long-Term Assets	$87.70M	$91.97M	$91.97M
YoY Change	-18.79%	-21.57%	-21.57%
TOTAL ASSETS
Total Short-Term Assets	$278.2M	$331.6M	$331.6M
Total Long-Term Assets	$87.70M	$91.97M	$91.97M
Total Assets	$365.9M	$423.5M	$423.5M
YoY Change	-32.06%	-30.58%	-30.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.353M	$17.96M	$17.96M
YoY Change	-93.89%	-41.61%	-41.61%
Accrued Expenses	$164.3M	$172.9M	$186.9M
YoY Change	4.61%	-21.33%	-18.6%
Deferred Revenue	$12.86M	$12.74M
YoY Change	-22.02%	0.01%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$40.00K	$40.00K
YoY Change		11.11%	11.11%
Total Short-Term Liabilities	$196.7M	$217.7M	$217.7M
YoY Change	-22.77%	-20.43%	-20.43%
LONG-TERM LIABILITIES
Long-Term Debt	$89.66M	$89.80M	$89.80M
YoY Change	418.98%	426.57%	426.57%
Other Long-Term Liabilities	$3.786M	$2.858M	$278.3M
YoY Change	-46.4%	-55.62%	-13.3%
Total Long-Term Liabilities	$3.786M	$2.858M	$368.1M
YoY Change	-46.4%	-55.62%	8.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$196.7M	$217.7M	$217.7M
Total Long-Term Liabilities	$3.786M	$2.858M	$368.1M
Total Liabilities	$552.0M	$585.7M	$627.7M
YoY Change	-2.72%	-4.23%	-0.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.875B	-$1.842B
YoY Change	14.71%	18.25%
Common Stock	$995.0K	$988.0K
YoY Change	3.0%	4.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$228.1M	-$204.2M	-$204.2M
YoY Change
Total Liabilities & Shareholders Equity	$365.9M	$423.5M	$423.5M
YoY Change	-32.06%	-30.58%	-30.58%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$32.93M	-$56.23M	-$284.2M
YoY Change	-57.07%	-15.03%	-3.21%
Depreciation, Depletion And Amortization	$810.0K	$1.875M	$9.500M
YoY Change	-68.14%	-30.3%	-5.0%
Cash From Operating Activities	-$59.29M	-$18.32M	-$315.0M
YoY Change	-41.64%	-65.11%	115.87%
INVESTING ACTIVITIES
Capital Expenditures	$29.00K	$251.0K	$2.519M
YoY Change	-95.09%	-24.62%	-32.67%
Acquisitions
YoY Change
Other Investing Activities	$51.31M	$10.49M	$156.2M
YoY Change	-50.7%	635.83%	22.15%
Cash From Investing Activities	$51.28M	$10.24M	$153.7M
YoY Change	-50.45%	837.05%	72.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.731M
YoY Change			-10.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-165.0K	-246.0K	122.7M
YoY Change	-100.52%	-100.51%	162.42%
NET CHANGE
Cash From Operating Activities	-59.29M	-18.32M	-315.0M
Cash From Investing Activities	51.28M	10.24M	153.7M
Cash From Financing Activities	-165.0K	-246.0K	122.7M
Net Change In Cash	-7.954M	-8.325M	-42.01M
YoY Change	-124.21%	203.17%	170.64%
FREE CASH FLOW
Cash From Operating Activities	-$59.29M	-$18.32M	-$315.0M
Capital Expenditures	$29.00K	$251.0K	$2.519M
Free Cash Flow	-$59.32M	-$18.57M	-$317.5M
YoY Change	-41.95%	-64.86%	112.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000921299
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36740
CY2023	dei	Entity Registrant Name EntityRegistrantName	FIBROGEN, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0357827
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	409 Illinois Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2023	dei	City Area Code CityAreaCode	415
CY2023	dei	Local Phone Number LocalPhoneNumber	978-1200
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023	dei	Trading Symbol TradingSymbol	FGEN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	261500000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98771247
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113688000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155700000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	121898000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	266308000
CY2023Q4	fgen	Accounts Receivable Net Current Related Parties AccountsReceivableNetCurrentRelatedParties	6079000
CY2022Q4	fgen	Accounts Receivable Net Current Related Parties AccountsReceivableNetCurrentRelatedParties	12088000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12553000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16299000
CY2023Q4	us-gaap	Inventory Net InventoryNet	41565000
CY2022Q4	us-gaap	Inventory Net InventoryNet	40436000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	41855000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14083000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	331559000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	492826000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1658000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2072000
CY2023Q4	fgen	Long Term Investment Excluding Equity Method Investments LongTermInvestmentExcludingEquityMethodInvestments	0
CY2022Q4	fgen	Long Term Investment Excluding Equity Method Investments LongTermInvestmentExcludingEquityMethodInvestments	4348000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13126000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20605000
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	5290000
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	5061000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68093000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	79893000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3803000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5282000
CY2023Q4	us-gaap	Assets Assets	423529000
CY2022Q4	us-gaap	Assets Assets	610087000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17960000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	30758000
CY2023Q4	fgen	Other Liabilities Current Due To Related Parties OtherLiabilitiesCurrentDueToRelatedParties	39814000
CY2022Q4	fgen	Other Liabilities Current Due To Related Parties OtherLiabilitiesCurrentDueToRelatedParties	63886000
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	172891000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	219773000
CY2023Q4	fgen	Due To Related Parties Deferred Revenue Current DueToRelatedPartiesDeferredRevenueCurrent	7220000
CY2022Q4	fgen	Due To Related Parties Deferred Revenue Current DueToRelatedPartiesDeferredRevenueCurrent	9259000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12740000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12739000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14077000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10292000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	217668000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	273562000
CY2023Q4	fgen	Accrued Product Development Costs AccruedProductDevelopmentCosts	17763000
CY2022Q4	fgen	Accrued Product Development Costs AccruedProductDevelopmentCosts	16917000
CY2023Q4	fgen	Due To Related Parties Deferred Revenue Noncurrent DueToRelatedPartiesDeferredRevenueNoncurrent	9705000
CY2022Q4	fgen	Due To Related Parties Deferred Revenue Noncurrent DueToRelatedPartiesDeferredRevenueNoncurrent	31044000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	157555000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	185722000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	66537000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	79593000
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	71934000
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0
CY2023Q4	fgen	Liability Related To Sale Of Future Revenues Non Current LiabilityRelatedToSaleOfFutureRevenuesNonCurrent	51413000
CY2022Q4	fgen	Liability Related To Sale Of Future Revenues Non Current LiabilityRelatedToSaleOfFutureRevenuesNonCurrent	49333000
CY2023Q4	fgen	Other Liabilities Noncurrent Due To Related Parties OtherLiabilitiesNoncurrentDueToRelatedParties	656000
CY2022Q4	fgen	Other Liabilities Noncurrent Due To Related Parties OtherLiabilitiesNoncurrentDueToRelatedParties	0
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2858000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6440000
CY2023Q4	us-gaap	Liabilities Liabilities	585728000
CY2022Q4	us-gaap	Liabilities Liabilities	611567000
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	21480000
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	125000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	125000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98770000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98770000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94166000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94166000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	988000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	942000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1643641000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1541019000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6875000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5720000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1841920000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1557688000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-204166000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21447000
CY2023Q4	us-gaap	Nonredeemable Noncontrolling Interest NonredeemableNoncontrollingInterest	20487000
CY2022Q4	us-gaap	Nonredeemable Noncontrolling Interest NonredeemableNoncontrollingInterest	19967000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-183679000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1480000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	423529000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	610087000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147752000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	140734000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	235309000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	18848000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	20280000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	12871000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	282861000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	296791000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	387043000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	115252000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	124688000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	123925000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	12606000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	0
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	429567000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	441759000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	523839000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-281815000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-301025000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-288530000
CY2023	us-gaap	Interest Expense InterestExpense	15532000
CY2022	us-gaap	Interest Expense InterestExpense	1440000
CY2021	us-gaap	Interest Expense InterestExpense	1075000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10480000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7596000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1078000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5052000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6156000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2153000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-286867000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-294869000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-290683000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	358000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	347000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2638000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1573000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1007000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-284232000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-293654000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290023000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.92
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.92
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.14
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.14
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97303000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97303000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93582000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93582000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92349000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92349000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-284232000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-293654000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290023000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3712000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	75000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1235000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2557000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1632000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-899000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1155000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1557000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	336000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-285387000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-295211000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	71161000
CY2023	fgen	Acquired In Process Research And Development Expenses AcquiredInProcessResearchAndDevelopmentExpenses	24636000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-289687000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	441449000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290023000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-899000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1235000
CY2021	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	5494000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	71161000
CY2021	fgen	Conversion Of Subsidiarys Convertible Note Payable ConversionOfSubsidiarysConvertibleNotePayable	696000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229113000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-293654000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1632000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	75000
CY2022	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	-983000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65601000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1480000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-284232000
CY2023	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	520000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2557000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3712000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48407000
CY2023	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	3494000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50767000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-183679000
CY2023	us-gaap	Profit Loss ProfitLoss	-284232000
CY2022	us-gaap	Profit Loss ProfitLoss	-293654000
CY2021	us-gaap	Profit Loss ProfitLoss	-290023000
CY2023	us-gaap	Depreciation Depreciation	9518000
CY2022	us-gaap	Depreciation Depreciation	10017000
CY2021	us-gaap	Depreciation Depreciation	10170000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	412000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	587000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4639000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5061000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1619000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2482000
CY2023	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	0
CY2022	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	0
CY2021	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	-30000
CY2023	fgen	Investment Gain Loss In Unconsolidated Variable Interest Entity InvestmentGainLossInUnconsolidatedVariableInterestEntity	2638000
CY2022	fgen	Investment Gain Loss In Unconsolidated Variable Interest Entity InvestmentGainLossInUnconsolidatedVariableInterestEntity	1573000
CY2021	fgen	Investment Gain Loss In Unconsolidated Variable Interest Entity InvestmentGainLossInUnconsolidatedVariableInterestEntity	1007000
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-4000
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-233000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	50767000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	65601000
CY2022	fgen	Acquired In Process Research And Development Expenses AcquiredInProcessResearchAndDevelopmentExpenses	0
CY2021	fgen	Acquired In Process Research And Development Expenses AcquiredInProcessResearchAndDevelopmentExpenses	60000000
CY2023	fgen	Non Cash Interest Expense Related To Sale Of Future Revenues NonCashInterestExpenseRelatedToSaleOfFutureRevenues	7734000
CY2022	fgen	Non Cash Interest Expense Related To Sale Of Future Revenues NonCashInterestExpenseRelatedToSaleOfFutureRevenues	1036000
CY2021	fgen	Non Cash Interest Expense Related To Sale Of Future Revenues NonCashInterestExpenseRelatedToSaleOfFutureRevenues	0
CY2023	fgen	Dividend Received From Unconsolidated Variable Interest Entity DividendReceivedFromUnconsolidatedVariableInterestEntity	2255000
CY2022	fgen	Dividend Received From Unconsolidated Variable Interest Entity DividendReceivedFromUnconsolidatedVariableInterestEntity	0
CY2021	fgen	Dividend Received From Unconsolidated Variable Interest Entity DividendReceivedFromUnconsolidatedVariableInterestEntity	0
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	1000000
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	-271000
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	-5000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-6009000
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-1158000
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-6803000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3433000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-765000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-25180000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1695000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10999000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14158000
CY2023	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	0
CY2022	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	0
CY2021	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	889000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	28165000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4916000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9854000
CY2023	fgen	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-11704000
CY2022	fgen	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-10908000
CY2021	fgen	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-4209000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-256000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-263000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4412000
CY2023	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	0
CY2022	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	0
CY2021	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	-1118000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-15514000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5909000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	805000
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-24072000
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	63882000
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-20000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-49778000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	90556000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	16380000
CY2023	fgen	Increase Decrease In Operating Lease Liabilities Current IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent	3820000
CY2022	fgen	Increase Decrease In Operating Lease Liabilities Current IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent	-547000
CY2021	fgen	Increase Decrease In Operating Lease Liabilities Current IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent	503000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-23378000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	11211000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	21549000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-28166000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4130000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	57637000
CY2023	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	-11000
CY2022	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	33000
CY2021	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	-75000
CY2023	fgen	Increase Decrease In Operating Lease Liabilities Non Current IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent	-12998000
CY2022	fgen	Increase Decrease In Operating Lease Liabilities Non Current IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent	-8994000
CY2021	fgen	Increase Decrease In Operating Lease Liabilities Non Current IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent	-4043000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2573000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-18250000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-12089000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-315021000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-145933000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82232000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2519000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3741000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5186000
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	35000000
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	25000000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	251830000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	164023000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	484144000
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	656000
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
CY2023	fgen	Proceeds From Sales Of Available For Sale Securities ProceedsFromSalesOfAvailableForSaleSecurities	6729000
CY2022	fgen	Proceeds From Sales Of Available For Sale Securities ProceedsFromSalesOfAvailableForSaleSecurities	7382000
CY2021	fgen	Proceeds From Sales Of Available For Sale Securities ProceedsFromSalesOfAvailableForSaleSecurities	4214000
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	400621000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	284492000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	83144000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	153657000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	89116000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-426972000
CY2023	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	74078000
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0
CY2021	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0
CY2023	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	2746000
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0
CY2023	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	148000
CY2022	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	135000
CY2021	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	5489000
CY2023	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	336000
CY2022	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2021	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	237000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5167000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7372000
CY2023	fgen	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	0
CY2022	fgen	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	49750000
CY2021	fgen	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	0
CY2023	fgen	Payments For Transaction Costs Related To Sale Of Future Revenues PaymentsForTransactionCostsRelatedToSaleOfFutureRevenues	0
CY2022	fgen	Payments For Transaction Costs Related To Sale Of Future Revenues PaymentsForTransactionCostsRelatedToSaleOfFutureRevenues	1453000
CY2021	fgen	Payments For Transaction Costs Related To Sale Of Future Revenues PaymentsForTransactionCostsRelatedToSaleOfFutureRevenues	0
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	48407000
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3731000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4184000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12701000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	122749000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46776000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-563000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-3397000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-5482000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2597000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42012000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15523000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-507170000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	155700000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	171223000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	678393000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	113688000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	155700000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	171223000
CY2023	fgen	Non Cash Acquisition In Fortis NonCashAcquisitionInFortis	-22000000
CY2022	fgen	Non Cash Acquisition In Fortis NonCashAcquisitionInFortis	0
CY2021	fgen	Non Cash Acquisition In Fortis NonCashAcquisitionInFortis	0
CY2023	us-gaap	Interest Paid Net InterestPaidNet	54000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	104000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	94000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	103000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	428000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1009000
CY2023	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	0
CY2022	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	0
CY2021	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	35000000
CY2023	fgen	Balance In Other Receivables Related To Stock Option Exercise BalanceInOtherReceivablesRelatedToStockOptionExercise	0
CY2022	fgen	Balance In Other Receivables Related To Stock Option Exercise BalanceInOtherReceivablesRelatedToStockOptionExercise	0
CY2021	fgen	Balance In Other Receivables Related To Stock Option Exercise BalanceInOtherReceivablesRelatedToStockOptionExercise	165000
CY2023	fgen	Conversion Of Subsidiarys Convertible Note Payable To Non Controlling Interests ConversionOfSubsidiarysConvertibleNotePayableToNonControllingInterests	0
CY2022	fgen	Conversion Of Subsidiarys Convertible Note Payable To Non Controlling Interests ConversionOfSubsidiarysConvertibleNotePayableToNonControllingInterests	0
CY2021	fgen	Conversion Of Subsidiarys Convertible Note Payable To Non Controlling Interests ConversionOfSubsidiarysConvertibleNotePayableToNonControllingInterests	696000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue and deferred revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation (as defined and discussed under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> below). On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries, corporate bonds, commercial paper and money market funds. Any remaining cash is deposited with major financial institutions primarily in the U.S., China and the Cayman Islands. At times, such deposits may be in excess of insured limits. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.64%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:14.4%;"></td> <td style="width:1%;"></td> <td style="width:1.28%;"></td> <td style="width:1%;"></td> <td style="width:14.4%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Falikang — Related party</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AstraZeneca</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the aggregate accounts receivable related to roxadustat sales in China from distributors represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of the consolidated accounts receivable, with no material balance from any individual distributor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	fgen	Highly Liquid Investment Maturity Period HighlyLiquidInvestmentMaturityPeriod	three months or less
CY2023Q4	fgen	Restricted Time Deposits Noncurrent RestrictedTimeDepositsNoncurrent	1700000
CY2022Q4	fgen	Restricted Time Deposits Noncurrent RestrictedTimeDepositsNoncurrent	2100000
CY2023	fgen	Short Term Investments Maximum Maturity Period ShortTermInvestmentsMaximumMaturityPeriod	P12M
CY2023	fgen	Long Term Investments Minimum Maturity Period LongTermInvestmentsMinimumMaturityPeriod	P12M
CY2023	fgen	Short Term Investments Maximum Maturity Period ShortTermInvestmentsMaximumMaturityPeriod	P12M
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2023	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.
CY2023	fgen	Description Of Sales Return DescriptionOfSalesReturn	distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product’s expiration date.
CY2023Q4	fgen	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	20400000
CY2022Q4	fgen	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	10500000
CY2021Q4	fgen	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	0
CY2021Q4	fgen	Fair Value Assets Level2 To Level1 Transfer Amount FairValueAssetsLevel2ToLevel1TransferAmount	0
CY2023Q4	fgen	Finance Lease Right Of Use Assets Cost FinanceLeaseRightOfUseAssetsCost	2478000
CY2022Q4	fgen	Finance Lease Right Of Use Assets Cost FinanceLeaseRightOfUseAssetsCost	2367000
CY2023Q4	fgen	Finance Lease Accumulated Amortization FinanceLeaseAccumulatedAmortization	2325000
CY2022Q4	fgen	Finance Lease Accumulated Amortization FinanceLeaseAccumulatedAmortization	1932000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	153000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	435000
CY2023Q4	fgen	Operating Lease Right Of Use Assets Cost OperatingLeaseRightOfUseAssetsCost	103010000
CY2022Q4	fgen	Operating Lease Right Of Use Assets Cost OperatingLeaseRightOfUseAssetsCost	101990000
CY2023Q4	fgen	Operating Lease Accumulated Amortization OperatingLeaseAccumulatedAmortization	34917000
CY2022Q4	fgen	Operating Lease Accumulated Amortization OperatingLeaseAccumulatedAmortization	22097000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68093000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	79893000
CY2023Q4	fgen	Finance Lease And Operating Lease Assets FinanceLeaseAndOperatingLeaseAssets	68246000
CY2022Q4	fgen	Finance Lease And Operating Lease Assets FinanceLeaseAndOperatingLeaseAssets	80328000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	40000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14077000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10292000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	104000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	137000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	66537000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	79593000
CY2023Q4	fgen	Finance Lease And Operating Lease Liability FinanceLeaseAndOperatingLeaseLiability	80758000
CY2022Q4	fgen	Finance Lease And Operating Lease Liability FinanceLeaseAndOperatingLeaseLiability	90058000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	412000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	587000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4639000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	628000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	17006000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	17125000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	10722000
CY2023	us-gaap	Sublease Income SubleaseIncome	3024000
CY2022	us-gaap	Sublease Income SubleaseIncome	3373000
CY2021	us-gaap	Sublease Income SubleaseIncome	1271000
CY2023	us-gaap	Lease Cost LeaseCost	14395000
CY2022	us-gaap	Lease Cost LeaseCost	14339000
CY2021	us-gaap	Lease Cost LeaseCost	14718000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	14463000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	15497000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	10022000
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	9000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	629000
CY2023	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	148000
CY2022	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	135000
CY2021	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	5489000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	131000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	261000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	450000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1278000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1704000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3585000
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0617
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.062
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0475
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0475
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	121874000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	30000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	47000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	17554000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	39000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	18836000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	39000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18082000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	37000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	18476000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	17401000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	162000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	90349000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	18000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9735000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	144000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	80614000
CY2023Q4	us-gaap	Cash Cash	63396000
CY2022Q4	us-gaap	Cash Cash	135819000
CY2023Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	36016000
CY2022Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	0
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	12288000
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	19881000
CY2023Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	1988000
CY2022Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	0
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113688000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155700000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	121898000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	273189000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2538000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	270656000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	9971000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	3495000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	5000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	13466000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	6000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	31538000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	170000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	159627000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2368000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	191165000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2538000
CY2023	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1376000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1241000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	34614000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	36003000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5575000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3192000
CY2023Q4	us-gaap	Inventory Net InventoryNet	41565000
CY2022Q4	us-gaap	Inventory Net InventoryNet	40436000
CY2023Q4	us-gaap	Supplies Supplies	26481000
CY2022Q4	us-gaap	Supplies Supplies	17488000
CY2023Q4	fgen	Deferred Revenues From Associated Contracts DeferredRevenuesFromAssociatedContracts	-26481000
CY2022Q4	fgen	Deferred Revenues From Associated Contracts DeferredRevenuesFromAssociatedContracts	-17488000
CY2023Q4	fgen	Supplies Net SuppliesNet	0
CY2022Q4	fgen	Supplies Net SuppliesNet	0
CY2023Q4	us-gaap	Loss Contingency Receivable Current LossContingencyReceivableCurrent	28500000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6644000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9730000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6711000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4353000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	41855000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14083000
CY2023Q4	us-gaap	Loss Contingency Receivable Current LossContingencyReceivableCurrent	28500000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	150056000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	149287000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	136930000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	128682000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13126000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20605000
CY2023	us-gaap	Depreciation Depreciation	9500000
CY2022	us-gaap	Depreciation Depreciation	10000000
CY2021	us-gaap	Depreciation Depreciation	10200000
CY2023Q4	fgen	Accrued Preclinical And Clinical Trial Current AccruedPreclinicalAndClinicalTrialCurrent	27663000
CY2022Q4	fgen	Accrued Preclinical And Clinical Trial Current AccruedPreclinicalAndClinicalTrialCurrent	57780000
CY2023Q4	fgen	Accrued Api And Bulk Drug Product Price True Up Current AccruedApiAndBulkDrugProductPriceTrueUpCurrent	50978000
CY2022Q4	fgen	Accrued Api And Bulk Drug Product Price True Up Current AccruedApiAndBulkDrugProductPriceTrueUpCurrent	75055000
CY2023Q4	fgen	Litigation Settlement Current LitigationSettlementCurrent	28500000
CY2022Q4	fgen	Litigation Settlement Current LitigationSettlementCurrent	0
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20267000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22562000
CY2023Q4	fgen	Accrued Co Promotion Expenses Current AccruedCoPromotionExpensesCurrent	10309000
CY2022Q4	fgen	Accrued Co Promotion Expenses Current AccruedCoPromotionExpensesCurrent	36677000
CY2023Q4	fgen	Accrued Profit Share Current AccruedProfitShareCurrent	7084000
CY2022Q4	fgen	Accrued Profit Share Current AccruedProfitShareCurrent	7280000
CY2023Q4	fgen	Property Taxes And Other Current PropertyTaxesAndOtherCurrent	6615000
CY2022Q4	fgen	Property Taxes And Other Current PropertyTaxesAndOtherCurrent	7691000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7103000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5480000
CY2023Q4	fgen	Liability Related To Sale Of Future Revenues Current LiabilityRelatedToSaleOfFutureRevenuesCurrent	5654000
CY2022Q4	fgen	Liability Related To Sale Of Future Revenues Current LiabilityRelatedToSaleOfFutureRevenuesCurrent	0
CY2023Q4	fgen	Accrued Restructuring Charge Current AccruedRestructuringChargeCurrent	3697000
CY2023Q4	fgen	Accrued Product Development Costs Excluding Interest AccruedProductDevelopmentCostsExcludingInterest	10400000
CY2022Q4	fgen	Accrued Restructuring Charge Current AccruedRestructuringChargeCurrent	0
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5021000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7248000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	172891000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	219773000
CY2023Q4	fgen	Accrued Api And Bulk Drug Product Price True Up Current AccruedApiAndBulkDrugProductPriceTrueUpCurrent	51000000
CY2023Q4	fgen	Accrued Litigation Settlement AccruedLitigationSettlement	28500000
CY2023Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.32
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	12600000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	8900000
CY2023Q4	fgen	Accrued Restructuring Charges AccruedRestructuringCharges	3700000
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	74100000
CY2023Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	900000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	7400000
CY2023Q4	fgen	Debt Instrument Accrued Interest DebtInstrumentAccruedInterest	400000
CY2022Q4	fgen	Liability Related To Sale Of Future Revenues LiabilityRelatedToSaleOfFutureRevenues	49333000
CY2023	fgen	Non Cash Interest Expense Related To Sale Of Future Revenues NonCashInterestExpenseRelatedToSaleOfFutureRevenues	7734000
CY2023Q4	fgen	Liability Related To Sale Of Future Revenues LiabilityRelatedToSaleOfFutureRevenues	57067000
CY2023	fgen	Liability Related To Sale Of Revenue Current LiabilityRelatedToSaleOfRevenueCurrent	5654000
CY2023	fgen	Liability Related To Sale Of Revenues Noncurrent LiabilityRelatedToSaleOfRevenuesNoncurrent	51413000
CY2023	fgen	Number Of Product Development Obligations NumberOfProductDevelopmentObligations	11
CY2022Q4	fgen	Accrued Product Development Costs Excluding Interest AccruedProductDevelopmentCostsExcludingInterest	10100000
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	7300000
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	6800000
CY2023Q4	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	30318000
CY2023Q4	us-gaap	Recorded Unconditional Purchase Obligation Due In Second Year RecordedUnconditionalPurchaseObligationDueInSecondYear	5973000
CY2023Q4	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	36291000
CY2021Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	5
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	28500000
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	28500000
	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	6
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98770000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94166000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11104000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9088000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4404000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3669000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10769000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	11524000
CY2023Q4	fgen	Common Stock Shares Reserved CommonStockSharesReserved	130999000
CY2022Q4	fgen	Common Stock Shares Reserved CommonStockSharesReserved	123820000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9088000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.19
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5738000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.27
CY2023	fgen	Stock Issued During Period Shares Stock Options Exercised Full Year StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear	122000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.42
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1725000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	22.49
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1875000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	34.38
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11104000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-286867000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.21
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	83000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10224000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.21
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y1M9D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	68000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4688000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.66
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y14D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.58
CY2023	fgen	Schedule Of Sharebased Compensation Restricted Stock Units Perfomance Based Restricted Stock And Total Shareholders Return Award Activity Tabletextblock ScheduleOfSharebasedCompensationRestrictedStockUnitsPerfomanceBasedRestrictedStockAndTotalShareholdersReturnAwardActivityTabletextblock	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activities of RSUs, PRSUs and TSR awards:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.928%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:15.017%;"></td> <td style="width:1%;"></td> <td style="width:1.26%;"></td> <td style="width:1%;"></td> <td style="width:19.796000000000003%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares <br/>(In thousands)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Fair Value at Grant</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2022</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,669</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.80</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,612</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.61</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,002</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.70</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,875</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20.58</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested at December 31, 2023</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,404</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.37</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	1648201
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.61
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.68
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.19
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50767000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65601000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	71161000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-294869000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-290683000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14983000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11962000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10416000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-328475000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-307056000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-268499000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	41608000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	12187000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22184000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	358000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	347000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	358000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	347000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	358000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	347000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2023	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	-0.011
CY2022	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	-0.025
CY2021	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	-0.018
CY2023	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.179
CY2022	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.163
CY2021	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.168
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.03
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.016
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.043
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.028
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.004
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	175257000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	166708000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	123156000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	106131000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	48396000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	49990000
CY2023Q4	fgen	Deferred Tax Assetstax Capitalized Research And Development Expenses DeferredTaxAssetstaxCapitalizedResearchAndDevelopmentExpenses	81697000
CY2022Q4	fgen	Deferred Tax Assetstax Capitalized Research And Development Expenses DeferredTaxAssetstaxCapitalizedResearchAndDevelopmentExpenses	45125000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9155000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8616000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	17189000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	18442000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5475000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4929000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	24792000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	21624000
CY2023Q4	fgen	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	63146000
CY2022Q4	fgen	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	69159000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	698000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1277000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	548961000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	492001000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	534967000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	477969000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13994000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14032000
CY2023Q4	fgen	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	10511000
CY2022Q4	fgen	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	13101000
CY2023Q4	fgen	Deferred Tax Liabilities Non Deductibale Accrued Expenses DeferredTaxLiabilitiesNonDeductibaleAccruedExpenses	-3483000
CY2022Q4	fgen	Deferred Tax Liabilities Non Deductibale Accrued Expenses DeferredTaxLiabilitiesNonDeductibaleAccruedExpenses	-931000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	13994000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	14032000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	57000000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	68200000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	72000000
CY2023	fgen	Corporate Alternative Minimum Tax Percentage CorporateAlternativeMinimumTaxPercentage	0.15
CY2023	fgen	Percentage Of Excise Tax On Stock Buyback PercentageOfExciseTaxOnStockBuyback	0.01
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	81000000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	600000
CY2023	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Not Possible SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible	The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company’s effective tax rate.
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Revenues Revenues	147752000
CY2022	us-gaap	Revenues Revenues	140734000
CY2021	us-gaap	Revenues Revenues	235309000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13126000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20605000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	153000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	435000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68093000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	79893000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-020161-index-headers.html	Edgar Link	pending
0000950170-24-020161-index.html	Edgar Link	pending
0000950170-24-020161.txt	Edgar Link	pending
0000950170-24-020161-xbrl.zip	Edgar Link	pending
fgen-20231231.htm	Edgar Link	pending
fgen-20231231.xsd	Edgar Link	pending
fgen-ex10_5.htm	Edgar Link	pending
fgen-ex10_53.htm	Edgar Link	pending
fgen-ex23_1.htm	Edgar Link	pending
fgen-ex31_1.htm	Edgar Link	pending
fgen-ex31_2.htm	Edgar Link	pending
fgen-ex32_1.htm	Edgar Link	pending
fgen-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img64793345_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
fgen-20231231_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FGEN
FIBROGEN INC Stock $fgen

2024 Q1 Form 10-K Financial Statement

#000095017024020161 Filed on February 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FGEN FIBROGEN INC Stock $fgen

2024 Q1 Form 10-K Financial Statement

#000095017024020161 Filed on February 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FGEN
FIBROGEN INC Stock $fgen